PharmiWeb

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

BioNxt Solutions Inc.: BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery s ...

Lateral Flow Assay Market Projected to Reach US$ 17.66 Billion by 2035, Reflecting Ongoing Innovation and IP Activity | Astute Analytica

Future expansion hinges on integrating digital connectivity with lab-quality sensitivity to solidify decentralized care.
Scientific Research Publishing

Implementing an Electrocardiogram Suite in the Emergency Department to Decrease Door-to-EKG Time ()

Implementing an Electrocardiogram Suite in the Emergency Department to Decrease Door-to-EKG Time ...